Key result
In a computational model of atrial fibrillation, PITX2+/- -deficient AF had a higher termination rate with class IC antiarrhythmic drugs compared to wild-type AF.
Why the study?
Antiarrhythmic drug efficacy varies in AF patients and the PITX2 gene affects responsiveness, prompting exploration of virtual drug responses across genotypes using in silico modeling.
Do virtual antiarrhythmic drugs alter electrophysiological parameters and AF termination rates differently in PITX2+/- deficient versus wild-type AF models?
Do virtual antiarrhythmic drugs alter electrophysiological parameters and AF termination rates differently in PITX2+/- deficient versus wild-type AF models?
Patient-specific computational modeling demonstrates that PITX2+/- deficient atrial fibrillation has distinct wave dynamics and is more susceptible to termination by class IC antiarrhythmic drugs than wild-type AF.
Answers are grounded in this paper and cite their sources.
Does not support genotype-guided AAD selection; leaves open whether PITX2 variants modify class IC response in patients.
Background: The efficacy of antiarrhythmic drugs (AAD) can vary in patients with atrial fibrillation (AF), and the PITX2 gene affects the responsiveness of AADs. We explored the virtual AAD (V-AAD) responses between wild-type and PITX2 +/− -deficient AF conditions by realistic in silico AF modeling. Methods: We tested the V-AADs in AF modeling integrated with patients' 3D-computed tomography and 3D-electroanatomical mapping, acquired in 25 patients (68% male, 59.8 ± 9.8 years old, 32.0% paroxysmal type). The ion currents for the PITX2 +/− deficiency and each AAD (amiodarone, sotalol, dronedarone, flecainide, and propafenone) were defined based on previous publications. Results: We compared the wild-type and PITX2 +/− deficiency in terms of the action potential duration (APD 90 ), conduction velocity (CV), maximal slope of restitution (Smax), and wave-dynamic parameters, such as the dominant frequency (DF), phase singularities (PS), and AF termination rates according to the V-AADs. The PITX2 +/− -deficient model exhibited a shorter APD 90 ( p < 0.001), a lower Smax ( p < 0.001), mean DF ( p = 0.012), PS number ( p < 0.001), and a longer AF cycle length (AFCL, p = 0.011). Five V-AADs changed the electrophysiology in a dose-dependent manner. AAD-induced AFCL lengthening ( p < 0.001) and reductions in the CV ( p = 0.033), peak DF ( p < 0.001), and PS number ( p < 0.001) were more significant in PITX2 +/− -deficient than wild-type AF. PITX2 +/− -deficient AF was easier to terminate with class IC AADs than the wild-type AF ( p = 0.018). Conclusions: The computational modeling-guided AAD test was feasible for evaluating the efficacy of multiple AADs in patients with AF. AF wave-dynamic and electrophysiological characteristics are different among the PITX2 -deficient and the wild-type genotype models.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2021) studied Atrial Fibrillation (n=25). Virtual Class IC antiarrhythmic drugs (flecainide, propafenone) in PITX2+/- deficient model vs. Wild-type AF model was evaluated on AF termination rate with class IC AADs (p=0.018). In a computational model of atrial fibrillation, PITX2+/- -deficient AF had a higher termination rate with class IC antiarrhythmic drugs compared to wild-type AF.
Synapse has enriched 10 related papers. Consider them for comparative context: